Ingested interferon-α prevents allograft islet transplant rejection

Transplantation

Volumn 69, Issue 10, 2000, Pages 2162-2166

  Brod, Staley A ^a   Katz, Stephen ^b   Phan, Tammy ^b   Stepkowski, Stanislaw ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTIMMUNE;

ADOLESCENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; GRAFT REJECTION; IMMUNOSUPPRESSIVE TREATMENT; INGESTION; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL;

EID: 0034720549     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200005270-00035     Document Type: Article

References (51)

1. Brod SA, Burns DK. Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferons. Neurology 1994; 44(6): 1144.
2. Brod SA, Khan M, Kerman RH, Pappolla M. Oral administration of human or murine interferon alpha suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis. J Neuroimmunol 1995; 58(1): 61.
3. Brod SA, Scott M, Burns DK, Phillips JT. Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type 1 interferons. J Interferon Cytokine Res 1995; 15(2): 115.
4. Brod S. Effect of oral administration of type 1 interferon on experimental autoimmune encephalomyelitis. In: Reder AT, ed. Interferon therapy in multiple sclerosis. New York, Basel, Hong Kong: Marcel Dekker, Inc., 1997: 245.
5. Brod SA, Khan M. Oral administration of IFN-alpha is superior to subcutaneous administration of IFN-alpha in the suppression of chronic relapsing experimental autoimmune encephalomyelitis. J Autoimmun 1996; 9(1): 11.
6. + T cells from murine IFN-α fed donor mice inhibits actively induced experimental autoimmune encephalomyelitis in recipients and is associated with decreasing TNF-α secretion. J Immunother 1999 (in press).
7. Vriesendorp FJ, Flynn RE, Khan M, Pappolla MA, Brod SA. Oral administration of type I interferon modulates the course of experimental allergic neuritis. Autoimmunity 1996; 24(3): 157.
8. Brod SA. Gut response: therapy with ingested immunomodulatory proteins. Arch Neurol 1997; 54(10): 1300.
9. Brod SA, Kerman RH, Nelson LD, et al. Ingested IFN-alpha has biological effects in humans with relapsing-remitting multiple sclerosis. Mult Scler 1997; 3(1): 1.
10. Serreze D, Leiter E. Genetic and pathogenic basis of autoimmune diabetes in NOD mice. Curr Opin Immunol 1994; 6: 900.
11. Hanafusa T, Miyagawa J-I, Nakajima H, et al. The NOD mouse. Diab Res Clin Prac 1994; 24 (suppl): S307.
12. Wicker L, Todd J, Petersen L. Genetic control of autoimmune diabetes in the NOD mouse. Annu Rev Immunol 1995; 13: 179.
13. Brod S, Darcan S, Malone M, Pappolla M, Nelson L. Ingested IFN-α suppresses IDDM in the NOD mouse. Diabetologia 1998; 41: 1227.
14. Foulis AK, Liddle CN, Farquharson MA, Richmond JA, Weir RS. The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 1986; 29(5): 267.
15. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [see comments]. N Engl J Med 1993; 329(14): 977.
16. Morel P, Kaufman DB, Field MJ, Lloveras JK, Matas AJ, Sutherland DE. Detrimental effect of prednisone on canine islet autograft function. Transplant Proc 1992; 24(3): 1048.
17. Tuch BE, De Silva C, Keogh GW, Simpson AM, Smith MS. Survival of allografted fetal pig pancreatic islet-like cell clusters [ICCs]. Transplant Proc 1995; 27(6): 3375.
18. Sandberg JO, Andersson A. Toxicity in vivo of different immunosuppressive drugs in fetal porcine pancreatic islets. Transplantation 1996; 61(8): 1211.
19. Mellert J, Hering BJ, Liu X, et al. Successful islet auto- and allotransplantation in diabetic pigs. Transplantation 1998; 66(2): 200.
20. Ueki M, Yasunami Y, Ina K, et al. Diabetogenic effects of FK506 on renal subcapsular islet isografts in rat. Diabetes Res Clin Pract 1993; 20(1): 11.
21. Ochiai M, Arita S, Nagai T, et al. Islet toxicity of FK506 measured in canine autografts. Transplant Proc 1998; 30(2): 663.
22. Kendall DM, Robertson RP. Pancreas and islet transplantation in humans. Diabetes Metab 1996; 22(3): 157.
23. Bretzel RG, Hering BJ, Federlin KF. Islet cell transplantation in diabetes mellitus: from bench to bedside. Exp Clin Endocrinol Diabetes 1995; 103 (suppl 2): 143.
24. Casteels K, Waer M, Laureys J, Valckx D, Depovere J, Bouillon R, Mathieu C. Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic nonobese diabetic mice by a combination of a vitamin D3 analog and cyclosporine. Transplantation 1998; 65(9): 1225.
25. Weir G, Hollister J, Davalli A, Bonner-Weir S. Islet isolation from rodent pancreas. In: Lanza R, Chick W, ed. Procurement of pancreatic islets. Austin, TX: RG Landes, 1994: 53.
26. Brod SA, Nelson L, Jin R, Wolinsky JS. Ingested Interferon alpha induces Mx mRNA. Cytokine 1999; 11(7): 492.
27. Wahoff D, Papalois B, Leone J, Aasheim T, Gilmore T, Sutherland DE. The effect of 15-deoxyspergualin on islet allograft survival in the canine model. Transplant Proc 1996; 28(2): 912.
28. Tufveson G, Gannedahl G. Deoxyspergualin: a different and intriguing immunosuppressant. Transplant Proc 1994; 26(5): 3029.
29. Guo Z, Mital D, Shen J, et al. Immunosuppression preventing concordant xenogeneic islet graft rejection is not sufficient to prevent recurrence of autoimmune diabetes in nonobese diabetic mice. Transplantation 1998; 65(10): 1310.
30. Koulmanda M, Kovarik J, Mandel TE. Effect of mycophenolate mofetil with and without anti-CD4 (GK1.5) on fetal islet iso-, allo-, and xenografts in NOD/Lt female mice. Transplant Proc 1997; 29(4): 2161.
31. Hao L, Wang Y, Chan SM, Lafferty KJ. Effect of mycophenolate mofetil on islet allografting to chemically induced or spontaneously diabetic animals. Transplant Proc 1992; 24(6): 2843.
32. Dron M, Tovey MG. Interferon α/β, gene structure and regulation. In: Baron S, Coppenhaver D, Dianzani F, et al., eds. Interferon: principles and medical applications. Galveston, TX: UTMB Press, 1992: 33.
33. Uze G, Lutfalla G, Knudson KE. α and β Interferons and their receptor and their friends and relations. J Interferon Cytokine Res 1995; 15: 3.
34. Pfeffer LM, Donner DD. The downregulation of IFN-α receptors in human lymphoblastoid cells: relation of cellular responsiveness to antiproliferative action of IFN-α. Cancer Res 1990; 50: 2654.
35. Pfeffer LM, Colamonici OR. Transmembrane signalling by interferon-alpha. Pharmacol Ther 1991; 52: 149.
36. Horisberger MA. Mx protein: function and mechanism of action. In: Baron S, Coppenhaver D, Dianzani F, et al., eds. Interferon: principles and medical applications. Galveston, TX: UTMB Press, 1992: 215.
37. Fleischmann WR Jr, Koren S, Fleischmann CM. Orally administered interferons exert their white blood cell suppressive effects via a novel mechanism. Proc Soc Exp Biol Med 1992; 201(2): 200.
38. Cantell K, Pyhala L. Circulating interferon in rabbits after administration by different routes. J Gen Virol 1973; 20: 97.
39. Gibson DM, Cotler S, Spiegel HE, Colburn WA. Pharmacokinetics of recombinant leucocyte A interferon following various routes and modes of administration to the dog. J Interferon Res 1985; 5: 403.
40. Wills RJ, Spiegel HE, Soike KF. Pharmacokinetics of recombinant alpha A interferon following I.V. infusion and bolus, I.M., and P.O. administrations to African green monkeys. J Interferon Res 1984; 4: 399.
41. ser. J Interferon Res 1992; 12: 411.
42. Roers A, Hochkeppel H, Horisberger M, Hovanessian A, Haller O. MxA gene expression after live virus vaccination: a sensitive marker for endogenous type I interferon. J Infect Dis 1994; 169(4): 807.
43. Brandtzaeg P. Overview of the mucosal immune system. Curr Top Microbiol Immunol 1989; 146: 13.
44. MacDonald TT. Immunosuppression caused by antigen feeding. II. Suppressor T cells mask Peyer's patch B cell priming to orally administered antigen. Eur J Immunol 1983; 13(2): 138.
45. Mattingly JA. Immunologic suppression after oral administration of antigen. III. Activation of suppressor-inducer cells in the Peyer's patches. Cell Immunol 1984; 86(1): 46.
46. Santos LM, al-Sabbagh A, Londono A, Weiner HL. Oral tolerance to myelin basic protein induces regulatory TGF-beta-secreting T cells in Peyer's patches of SJL mice. Cell Immunol 1994; 157(2): 439.
47. Ford W, Gowan J. The traffic of lymphocytes. Semin Hematol 1969; 6: 67.
48. Blalock JE, Baron S. Interferon induced transfer of viral resistance between animal cells. Nature 1977; 269: 422.
49. Butcher EC. The regulation of lymphocyte traffic. Curr Top Microbiol Immunol 1986; 128: 85.
50. Bocci V. Roles of interferon produced in physiological conditions: a speculative review. Immunology 1988; 64: 1.
51. Butcher E, Picker L. Lymphocyte homing and homeostasis. Science 1996; 272(5 April): 60.